Notice NOT-OD-19-055 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-164 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences for high school or undergraduate students or science teachers during the summer academic break. The proposed program needs to fit within the mission of the participating IC that the application is being submitted to and should not have a general STEM focus (see below and Table of IC-Specific Information and Points of Contact)

Notice NOT-HS-19-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-19-033 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to develop and evaluate Virtual Reality (VR) enhanced technologies that will support SUD treatment and recovery, provide treatment alternatives for chronic pain, or serve as next generation Clinical Research Tools which leverage data from the VR experience and identify digital markers that model SUD and comorbid mental illness disorders. The objective of Phase I (R43) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the VR platform in a larger sample. For VR digital therapeutics, data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA medical device.

Funding Opportunity RFA-DA-19-032 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to develop and evaluate Virtual Reality (VR) enhanced technologies that will support SUD treatment and recovery, provide treatment alternatives for chronic pain, or serve as next generation Clinical Research Tools which leverage data from the VR experience and identify digital markers that model SUD and comorbid mental illness disorders. The objective of Phase I (R43) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the VR platform in a larger sample. For VR digital therapeutics, data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA medical device.

Notice NOT-CA-19-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-033 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Childhood Cancer Survivorship, Treatment Access, and Research (STAR) Act of 2018 that is intended to maximize discovery and accelerate development and availability of promising childhood cancer treatments. The purpose of this initiative is to stimulate the scientific development of effective, feasible and scalable interventions to address adverse physical and psychosocial effects in survivors of pediatric and or adolescent/young adult (AYA) cancers. These interventions may be delivered by providers, communities, and/or health care systems This FOA requests applications from investigators to: (i) develop and test interventions that prevent, mitigate or manage adverse outcomes in pediatric and/or AYA cancer survivors; (ii) evaluate models of care that strengthen coordination, continuity and quality, reduce access barriers to needed services including follow-up care, and improve outcomes, across the survivor's lifespan. Development of interventions to address disparities in outcomes and/or access to needed care, and to address the needs of minority or medically underserved pediatric and/or AYA populations is of high priority.

Notice NOT-GM-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-DC-19-004 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-018 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-18-509 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the Coordinating Center (TNCC) that is currently supporting the research being performed by the Type 1 Diabetes TrialNet network. This FOA will support the TNCC in its oversight of the screening of relatives of individuals with type 1 diabetes (T1D) for monitoring and possible inclusion in intervention studies aimed at preservation of insulin-producing cells. The FOA will also support the TNCC in its design, conduct and continuation of intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D (as selected by the TrialNet Steering Committee). The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination, and public accessibility. The TNCC will also provide capitated payments, based on TrialNet-related activities, to Clinical Centers and Affiliate Sites. In addition, the TNCC will be responsible for issuing a Request for Proposals (RFP) to select Clinical Centers to conduct TrialNet clinical studies.

Funding Opportunity RFA-DK-18-008 from the NIH Guide for Grants and Contracts. This FOA invites applications to fund continuation of the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit. The main objective of the HUB is to develop creative approaches to screening, recruitment, and trial implementation, and to increase the operational efficiency and flexibility of the TrialNet network.

Notice NOT-OD-19-057 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-032 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.

Funding Opportunity RFA-CA-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA solicits U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Negotiable: Paramount Recruitment: Vice President of Bioinformatics Paramount is currently searching for a dynamic, senior bioinformatics leader for one of the country's fasted growing biotechs. Stevenage, England